Lipid-lowering update 2001: Aggressive new goals

Canadian Family Physician

Volumn 47, Issue FEB., 2001, Pages 303-309

  Fenske, Theodore K ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL INFORMATION; MYOSITIS; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SURVIVAL;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 0035102751     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Statistics Canada. Mortality - summary list of causes 1994. Ottawa, Ont: Statistics Canada; 1994. Catalogue no. 84-209-XPB,199.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau J, Rutherford J, Cole T, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
6. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels for the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
8. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998;82:3Q-12Q.
9. Teo KK. Coronary artery disease prevention: better management of dyslipidemias required. Can J Cardiol 1997;13(2):127-8.
10. Fodor G, Frohlich J, Genest J Jr, McPherson R. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. Can Med Assoc J 2000;162(10):1441-7.
11. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
12. Kannel WB, Abbott RD. The incidence and prognosis of myocardial infarction in women. The Framingham Study. In: Eaker ED, Packand B, Wenger NK, editors. Coronary heart disease in women. New York, NY: Haymakers Doyma; 1997. p. 208-14.
13. Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;208:605-13.
14. Santanello N, Barber B, Applegate W, Elam J, Curtis C, Hunninghake B, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997;45:8-14.
15. Vogt M, Cauley J, Newman A, Kuller L. Hulley S. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993;270:465-9.
16. Criqui M, Langer R, Fronek A. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
17. Buchwald H, Bourdages H, Campos C, Nguyen P, Williams S, Campbell G, et al. Impact of cholesterol reduction on peripheral arterial disease in the program on the surgical control of the hyperlipidemias (POSCH). Surgery 1996;120:672-9.
18. Haffner S, Legto S, Onnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
19. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Mathews DR, for the United Kingdom Prospective Diabetes Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ 1998;316(7134):823-8.
20. Leiter LA. Low density lipoprotein cholesterol: is lower better? Can J Cardiol 2000;16(Suppl A):1A-3A.
21. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97:1436-9.
22. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979:241:2035-9.
23. Pitt B, Waters D, Brown W, Van Boven A, Schwarte L, Title L, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341(2):70-6.
24. La Rosa JC. Effect of lowering LDL-C beyond currently recommended minimum targets - the Treating to New Targets (TNT) study, TNT Steering Committee [abstract]. XIII International Symposium on Drugs Affecting Lipid Metabolism. 1998 May 30 to June 3; Florence, Italy.
25. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
26. Walden C, Retzall B, Buck B, McCann B, Knopp R. Lipoprotein lipid response to the National Cholesterol Education Program Step II diet by hypercholesterolemic and combined hyperlipidemic women and men. Arterioscler Thromb Vase Biol 1997;17:375-82.
27. DeLorgeril M, Salen P, Martin JN. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation 1999;99(6):779-85.
28. Stein E, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81(14A):66-9B.
29. Knopp R. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
30. Vaughan C, Murphy M, Buckley B. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
31. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999;99:3227-33.
32. Schwartz G, Oliver M, Ezekowitz M, Ganz P, Waters D, Kane J, et al. Rationale and design of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578-81.
33. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
34. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946-52.
35. Bradford RH, Shear CL, Chremos AN. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
36. Feher MD, Foxton J, Banks D, Lant AF, Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolemia in patients with coronary artery disease. Br Heart J 1995;74:14-7.
37. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
38. Goldbourt U, Yaari S, Medalie J. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13.
39. Knopp R, Ginsberg J, Albers J. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50.
40. Rubins H, Robbins S, Collins D, Fye C, Andersen J, Elam M, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: for the Veteran Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
41. Stampfer MJ, Kraus RM, Ma J. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
42. Kesaniemi YA. Serum triglycerides and clinical benefit in lipid-lowering trials. Am J Cardiol 1998;81(4A):70-3B.
43. Ellen R, McPherson R, Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81 (4A):60-5B.